| Name | bcl 2 |
|---|---|
| Synonyms | Apoptosis regulator Bcl 2; B cell CLL/lymphoma 2; B cell lymphoma protein 2 alpha; B cell lymphoma protein 2 alpha isoform; BCL2; Bcl 2; B cell CLL/lymphoma 2s; B cell lymphoma protein 2 alphas… |
| Name | biphenyl |
|---|---|
| CAS | 1,1′-biphenyl |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 18413764 | Huang S, Sinicrope FA: BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 2008 Apr 15;68(8):2944-51. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to induce mitochondrial apoptotic signaling that can be negatively regulated by prosurvival Bcl-2 proteins. |
2(0,0,0,2) | Details |
| 18591385 | Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA: The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood. 2008 Oct 1;112(7):2906-16. Epub 2008 Jun 30. Overexpression of antiapoptotic members of the Bcl-2 family is observed in approximately 80% of B-cell lymphomas, contributing to intrinsic and acquired drug resistance. |
2(0,0,0,2) | Details |
| 19561125 | Hermanson D, Addo SN, Bajer AA, Marchant JS, Das SG, Srinivasan B, Al-Mousa F, Michelangeli F, Thomas DD, Lebien TW, Xing C: Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria. Mol Pharmacol. 2009 Sep;76(3):667-78. Epub 2009 Jun 26. Because of the antiapoptotic function of Bcl-2 family proteins on the endoplasmic reticulum (ER) and mitochondria, the effect of sHA 14-1 on both organelles was evaluated. sHA 14-1 induced ER release in human leukemic cells within 1 min, followed by induction of the ER stress-inducible transcription factor ATF4. Evaluation of the mitochondrial pathway showed that sHA 14-1 triggered a loss of mitochondrial transmembrane potential (Delta psi m) and weak caspase-9 activation, whereas thapsigargin had no effect. (R)-4-(3-Dimethylamino-1-phenylsulfanylmethyl-propylamino)-N-{4-[4-(4'-chl oro-biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoyl}-3-nitrobenzenesulfonamid e (ABT-737), a well established small-molecule Bcl-2 antagonist, rapidly induced loss of Delta psi m and caspase-9 activation but had no effect on the ER. |
2(0,0,0,2) | Details |
| 18507762 | Deng J, Qian Y, Geng L, Chen J, Wang X, Xie H, Yan S, Jiang G, Zhou L, Zheng S: Involvement of p38 mitogen-activated protein kinase pathway in honokiol-induced apoptosis in a human hepatoma cell line (hepG2). Liver Int. 2008 Dec;28(10):1458-64. Epub 2008 May 26. Western blots were used to analyse the expression of various proteins (procaspase-9, procaspase-3, cleaved caspase-3, cytochrome c, Bcl-2, Bax, Bad, Bcl-X (L) and p38). |
2(0,0,0,2) | Details |
| 18309326 | Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P, Dyer MJ, Cohen GM: A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ. 2008 May;15(5):820-30. Epub 2008 Feb 29. Primary chronic lymphocytic leukemia (CLL) cells are exquisitely sensitive to ABT-737, a small molecule BCL2-antagonist, which induces many of the classical biochemical and ultrastructural features of apoptosis, including BAX/BAK oligomerization, cytochrome c release, caspase activation and chromatin condensation. |
2(0,0,0,2) | Details |
| 19773376 | Kim KW, Moretti L, Mitchell LR, Jung DK, Lu B: Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model. Clin Cancer Res. 2009 Oct 1;15(19):6096-105. Epub 2009 Sep 22. |
2(0,0,0,2) | Details |
| 18056200 | Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A: The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 2007 Dec 1;13(23):7191-8. |
2(0,0,0,2) | Details |
| 17991446 | Marengo B, De Ciucis C, Verzola D, Pistoia V, Raffaghello L, Patriarca S, Balbis E, Traverso N, Cottalasso D, Pronzato MA, Marinari UM, Domenicotti C: Mechanisms of BSO (L-buthionine-S,R-sulfoximine)-induced cytotoxic effects in neuroblastoma. Free Radic Biol Med. 2008 Feb 1;44(3):474-82. Epub 2007 Oct 22. These results describe a novel pathway of apoptosis dependent on ROS formation and PKC-delta activation and independent of p53, bcl-2, and bax levels; the selective redox modulation of PKC-delta might be suggested as a potential strategy for sensitizing MYCN-amplified cells to therapeutic approaches. |
1(0,0,0,1) | Details |
| 18241858 | Lee SY, Yuk DY, Song HS, Yoon do Y, Jung JK, Moon DC, Lee BS, Hong JT: Growth inhibitory effects of obovatol through induction of apoptotic cell death in prostate and colon cancer by blocking of NF-kappaB. Eur J Pharmacol. 2008 Mar 17;582(1-3):17-25. Epub 2008 Jan 5. Correlated well with the induction of apoptosis, obovatol increased the expression of the apoptotic genes; Bax, caspase-3, caspase-9, whereas inhibited expression of anti-apoptotic genes; Bcl-2, inhibitor of apoptosis protein (IAP-1) and X chromosome IAP (XIAP) as well as the cell proliferation marker genes; Cox-2, c-Fos, c-Jun and cyclin D1. |
1(0,0,0,1) | Details |
| 19135778 | Park EJ, Min HY, Chung HJ, Hong JY, Kang YJ, Hung TM, Youn UJ, Kim YS, Bae K, Kang SS, Lee SK: Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. Cancer Lett. 2009 May 18;277(2):133-40. Epub 2009 Jan 9. Apoptosis caused by honokiol was also concomitant with the cleavage of caspases (caspase-3, -8, and -9) and Bid along with the suppressive expression of Bcl-2, but it was independent on the expression of Bax and p53. |
1(0,0,0,1) | Details |
| 19655415 | Yao K, Zhang L, Ye PP, Tang XJ, Zhang YD: Protective effect of magnolol against peroxide-induced oxidative stress in human lens epithelial cells. Am J Chin Med. 2009;37(4):785-96. Magnolol also inhibited H2O2-induced expressions of caspase-9 and caspase-3 and reduction of Bcl-2/Bax ratio. |
1(0,0,0,1) | Details |
| 19004807 | Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DC, Roberts AW: In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17961-6. Epub 2008 Nov 11. |
7(0,0,0,7) | Details |
| 19228717 | Kang MH, Reynolds CP: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009 Feb 15;15(4):1126-32. |
6(0,0,0,6) | Details |
| 19759519 | Iwasawa M, Miyazaki T, Nagase Y, Akiyama T, Kadono Y, Nakamura M, Oshima Y, Yasui T, Matsumoto T, Nakamura T, Kato S, Hennighausen L, Nakamura K, Tanaka S: The antiapoptotic protein Bcl-xL negatively regulates the bone-resorbing activity of osteoclasts in mice. J Clin Invest. 2009 Oct;119(10):3149-59. doi: 10.1172/JCI39819. Epub 2009 Sep 14. The B cell lymphoma 2 (Bcl-2) family member Bcl-xL has a well-characterized antiapoptotic function in lymphoid cells. |
1(0,0,0,1) | Details |
| 20023629 | Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang DC, Dixit VM: Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010 Jan 7;463(7277):103-7. Epub 2009 Dec 20. MCL1 is essential for the survival of stem and progenitor cells of multiple lineages, and is unique among pro-survival BCL2 family members in that it is rapidly turned over through the action of ubiquitin ligases. |
1(0,0,0,1) | Details |
| 19764793 | Pizzirani D, Roberti M, Grimaudo S, Di Cristina A, Pipitone RM, Tolomeo M, Recanatini M: Identification of biphenyl-based hybrid molecules able to decrease the intracellular level of Bcl-2 protein in Bcl-2 overexpressing leukemia cells. J Med Chem. 2009 Nov 12;52(21):6936-40. |
6(0,0,1,1) | Details |
| 19494271 | Bardwell PD, Gu J, McCarthy D, Wallace C, Bryant S, Goess C, Mathieu S, Grinnell C, Erickson J, Rosenberg SH, Schwartz AJ, Hugunin M, Tarcsa E, Elmore SW, McRae B, Murtaza A, Wang LC, Ghayur T: The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J Immunol. 2009 Jun 15;182(12):7482-9. |
6(0,0,0,6) | Details |
| 18369371 | Labi V, Grespi F, Baumgartner F, Villunger A: Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?. Cell Death Differ. 2008 Jun;15(6):977-87. Epub 2008 Mar 28. |
5(0,0,0,5) | Details |
| 20038799 | Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M: Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest. 2010 Jan;120(1):142-56. doi: 10.1172/JCI38942. Epub 2009 Dec 21. Here we have demonstrated that pharmacologic inhibition of FAO with etomoxir or ranolazine inhibited proliferation and sensitized human leukemia cells--cultured alone or on bone marrow stromal cells--to apoptosis induction by ABT-737, a molecule that releases proapoptotic Bcl-2 proteins such as Bak from antiapoptotic family members. |
1(0,0,0,1) | Details |
| 18454133 | Sandoval H, Thiagarajan P, Dasgupta SK, Schumacher A, Prchal JT, Chen M, Wang J: Essential role for Nix in autophagic maturation of erythroid cells. . Nature. 2008 Jul 10;454(7201):232-5. Epub 2008 May 4. Here we report a role for a Bcl-2 family member, Nix (also called Bnip3L), in the regulation of erythroid maturation through mitochondrial autophagy. |
1(0,0,0,1) | Details |
| 18604177 | Wade M, Rodewald LW, Espinosa JM, Wahl GM: BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death. Cell Cycle. 2008 Jul 1;7(13):1973-82. We show that sensitivity to apoptosis in cells with high Hdmx levels is restored by combined treatment with Nutlin and a Bcl-2 family member antagonist to activate Bax. |
1(0,0,0,1) | Details |
| 18381439 | Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL, Watkins DN, Rudin CM: Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008 Apr 1;68(7):2321-8. Bcl-2 is a central regulator of cell survival that is overexpressed in the majority of small cell lung cancers (SCLC) and contributes to both malignant transformation and therapeutic resistance. |
5(0,0,0,5) | Details |
| 19097992 | Yang TM, Barbone D, Fennell DA, Broaddus VC: Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol. 2009 Jul;41(1):14-23. Epub 2008 Dec 18. |
5(0,0,0,5) | Details |
| 20038611 | High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB: The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol. 2010 Mar;77(3):483-94. Epub 2009 Dec 28. |
5(0,0,0,5) | Details |
| 19737541 | Ugarenko M, Nudelman A, Rephaeli A, Kimura K, Phillips DR, Cutts SM: ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts. Biochem Pharmacol. 2010 Feb 1;79(3):339-49. Epub 2009 Sep 6. |
5(0,0,0,5) | Details |
| 18819468 | Tang Y, Zhang DY, Wu XM: [Progress in small-molecule inhibitors of Bcl-2 family proteins] . Yao Xue Xue Bao. 2008 Jul;43(7):669-77. |
5(0,0,0,5) | Details |
| 19805519 | Chen S, Dai Y, Pei XY, Grant S: Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol. 2009 Dec;29(23):6149-69. Epub 2009 Oct 5. |
5(0,0,0,5) | Details |
| 19246337 | Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE: ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol. 2009 May;75(5):1231-9. Epub 2009 Feb 25. Overexpression of Bcl-X (L), an antiapoptotic Bcl-2 family member, occurs in a majority of head and neck squamous cell carcinomas (HNSCCs) and correlates with chemotherapy resistance in this disease. |
4(0,0,0,4) | Details |
| 19244105 | VanBrocklin MW, Verhaegen M, Soengas MS, Holmen SL: Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res. 2009 Mar 1;69(5):1985-94. Epub 2009 Feb 24. To define the molecular mechanism underlying variable apoptotic sensitivity of melanoma cells to MEK inhibition, we examined the expression and subcellular localization of Bcl-2 family members in a comprehensive set of human melanoma cell lines. |
1(0,0,0,1) | Details |
| 18362892 | Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L, Araujo N, Pinna G, Larochette N, Zamzami N, Modjtahedi N, Harel-Bellan A, Kroemer G: Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene. 2008 Jul 10;27(30):4221-32. Epub 2008 Mar 24. In VDAC1-depleted cells, the failure of CDDP to activate Bax could be reversed by means of the Bcl-2/Bcl-X (L) antagonist ABT-737, which concomitantly restored CDDP cytotoxicity. |
1(0,0,0,1) | Details |
| 19839062 | Hikita H, Takehara T, Kodama T, Shimizu S, Hosui A, Miyagi T, Tatsumi T, Ishida H, Ohkawa K, Li W, Kanto T, Hiramatsu N, Hennighausen L, Yin XM, Hayashi N: BH3-only protein bid participates in the Bcl-2 network in healthy liver cells. Hepatology. 2009 Dec;50(6):1972-80. |
4(0,0,0,4) | Details |
| 18767026 | Azmi AS, Mohammad RM: Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol. 2009 Jan;218(1):13-21. |
4(0,0,0,4) | Details |
| 19380879 | Gallenne T, Gautier F, Oliver L, Hervouet E, Noel B, Hickman JA, Geneste O, Cartron PF, Vallette FM, Manon S, Juin P: Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol. 2009 Apr 20;185(2):279-90. |
4(0,0,0,4) | Details |
| 18398104 | Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP: Mechanism of synergy of N-(4-hydroxyphenyl) retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst. 2008 Apr 16;100(8):580-95. Epub 2008 Apr 8. BACKGROUND: ABT-737 is a pan-Bcl-2 inhibitor that has a wide range of single-agent activity against acute lymphoblastic leukemia (ALL) cell lines and xenografts. |
4(0,0,0,4) | Details |
| 18806758 | Vogler M, Dinsdale D, Dyer MJ, Cohen GM: Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009 Mar;16(3):360-7. Epub 2008 Sep 19. |
4(0,0,0,4) | Details |
| 18281560 | Hahm ER, Arlotti JA, Marynowski SW, Singh SV: Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin Cancer Res. 2008 Feb 15;14(4):1248-57. Levels of Bcl-2 family proteins in cell lysates and tumor supernatants were determined by immunoblotting. |
1(0,0,0,1) | Details |
| 19726085 | Cencic R, Carrier M, Trnkus A, Porco JA Jr, Minden M, Pelletier J: Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res. 2010 Apr;34(4):535-41. Epub 2009 Sep 1. Silvestrol shows synergy with standard-of-care agents in AML cell lines and synergizes with ABT-737, a small molecule inhibitor of Bcl-X (L) and Bcl-2. |
1(0,0,0,1) | Details |
| 18369342 | Yang JY, Della-Fera MA, Rayalam S, Baile CA: Enhanced effects of xanthohumol plus honokiol on apoptosis in 3T3-L1 adipocytes. Obesity (Silver Spring). 2008 Jun;16(6):1232-8. Epub 2008 Mar 27. Expression of apoptosis related proteins including cleaved poly (ADP- polymerase (PARP), cytochrome c, Bcl-2, caspase-3/7, phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and Akt was analyzed by western blotting. |
1(0,0,0,1) | Details |
| 20074268 | Atessahin A, Turk G, Yilmaz S, Sonmez M, Sakin F, Ceribasi AO: Modulatory Effects of and on Reproductive Dysfunction Induced by Polychlorinated Biphenyl (Aroclor 1254) in Male Rats. Basic Clin Pharmacol Toxicol. 2010 Jan 14. Body and reproductive organ weights, epididymal sperm characteristics, testicular tissue lipid peroxidation levels, antioxidant enzyme activities, histopathological changes and apoptosis via Bax and Bcl-2 genes were investigated. |
1(0,0,0,1) | Details |
| 19726685 | Lee EF, Czabotar PE, Yang H, Sleebs BE, Lessene G, Colman PM, Smith BJ, Fairlie WD: Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands. J Biol Chem. 2009 Oct 30;284(44):30508-17. Epub 2009 Sep 2. |
4(0,0,0,4) | Details |
| 18663354 | Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, Herold-Mende C, Roth W: Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene. 2008 Nov 6;27(52):6646-56. Epub 2008 Jul 28. |
4(0,0,0,4) | Details |
| 19390557 | Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, Cohen GM: Different forms of cell death induced by putative BCL2 inhibitors. . Cell Death Differ. 2009 Jul;16(7):1030-9. Epub 2009 Apr 24. |
4(0,0,0,4) | Details |
| 18451169 | Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M: Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008 May 1;68(9):3413-20. |
4(0,0,0,4) | Details |
| 19060243 | Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, Coomans C, Peart MJ, Newbold A, Lindemann RK, Johnstone RW: Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood. 2009 Feb 26;113(9):1982-91. Epub 2008 Dec 5. The apoptotic and therapeutic activities of the histone deacetylase inhibitor (HDACi) vorinostat are blocked by overexpression of Bcl-2 or Bcl-X (L). |
4(0,0,0,4) | Details |
| 19557638 | Jayanthan A, Howard SC, Trippett T, Horton T, Whitlock JA, Daisley L, Lewis V, Narendran A: Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma. 2009 Jul;50(7):1174-82. |
4(0,0,0,4) | Details |
| 18949058 | Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL: Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest. 2008 Nov;118(11):3651-9. Epub 2008 Oct 23. Here, we have shown that MEK inhibition also triggers limited apoptosis of human tumor cell lines with B-RAF mutations and that this effect was dependent on upregulation and dephosphorylation of the proapoptotic, Bcl-2 homology 3-only (BH3-only) Bcl-2 family member Bim. |
3(0,0,0,3) | Details |
| 19074726 | Chen J, Fiskus W, Eaton K, Fernandez P, Wang Y, Rao R, Lee P, Joshi R, Yang Y, Kolhe R, Balusu R, Chappa P, Natarajan K, Jillella A, Atadja P, Bhalla KN: Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood. 2009 Apr 23;113(17):4038-48. Epub 2008 Dec 12. There, Nur77 converts death resistance protein Bcl-2 into a killer protein, promoting cell death of cultured and patient-derived human CTCL cells. |
3(0,0,0,3) | Details |
| 18689543 | Stolz C, Hess G, Hahnel PS, Grabellus F, Hoffarth S, Schmid KW, Schuler M: Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood. 2008 Oct 15;112(8):3312-21. Epub 2008 Aug 8. |
3(0,0,0,3) | Details |
| 19088028 | Okumura K, Huang S, Sinicrope FA: Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res. 2008 Dec 15;14(24):8132-42. |
3(0,0,0,3) | Details |
| 19404643 | Howard AN, Bridges KA, Meyn RE, Chandra J: ABT-737, a BH3 mimetic, induces depletion and oxidative stress. Cancer Chemother Pharmacol. 2009 Dec;65(1):41-54. Epub 2009 Apr 29. METHODS: Jurkat human acute lymphocytic leukemia cells and HeLa cells transfected with a tet-regulated Bcl-2 expression system were treated with ABT-737 or its less active stereoisomer. |
3(0,0,0,3) | Details |
| 18807035 | Begley J, Vo DD, Morris LF, Bruhn KW, Prins RM, Mok S, Koya RC, Garban HJ, Comin-Anduix B, Craft N, Ribas A: Immunosensitization with a Bcl-2 small molecule inhibitor. . Cancer Immunol Immunother. 2009 May;58(5):699-708. Epub 2008 Sep 20. |
3(0,0,0,3) | Details |
| 17921043 | Zhang L, Ming L, Yu J: BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat. 2007 Dec;10(6):207-17. Epub 2007 Oct 24. Tumor cell survival is highly dependent on the expression of certain pro-survival Bcl-2 family proteins. |
3(0,0,0,3) | Details |
| 19060244 | Zeuner A, Pedini F, Francescangeli F, Signore M, Girelli G, Tafuri A, De Maria R: Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood. 2009 Feb 12;113(7):1522-5. Epub 2008 Dec 5. We found that erythroid precurors derived from patients with polycythemia vera (PV) with medium and high JAK2V617F mutation rates often express elevated levels of the antiapoptotic molecules Bcl-2 and Bcl-X (L) (5 of 12 patients with 3 to 7 times Bcl-2 and 3 of 12 patients with 4 to 7 times Bcl-X (L) than average normal controls) and are more resistant to myelosuppressive drugs than normal erythroblasts. |
3(0,0,0,3) | Details |
| 19737977 | Bray K, Chen HY, Karp CM, May M, Ganesan S, Karantza-Wadsworth V, DiPaola RS, White E: Bcl-2 modulation to activate apoptosis in prostate cancer. . Mol Cancer Res. 2009 Sep;7(9):1487-96. Epub 2009 Sep 8. |
3(0,0,0,3) | Details |
| 18987671 | Miller LA, Goldstein NB, Johannes WU, Walton CH, Fujita M, Norris DA, Shellman YG: BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J Invest Dermatol. 2009 Apr;129(4):964-71. Epub 2008 Nov 6. The Bcl-2 family is important in modulating sensitivity to anticancer drugs in many cancers, including melanomas. |
3(0,0,0,3) | Details |
| 19372561 | Hauck P, Chao BH, Litz J, Krystal GW: Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther. 2009 Apr;8(4):883-92. To understand the molecular basis for variable sensitivity to the BH3 mimetic drug ABT-737, the abundance of Bcl-2 family members was assayed in a panel of small cell lung cancer cell lines whose sensitivity varied over a 2-log range. |
3(0,0,0,3) | Details |
| 18440692 | Li Z, Liu Y, Zhao X, Pan X, Yin R, Huang C, Chen L, Wei Y: Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells. Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):95-102. Epub 2008 Apr 28. Expression of Bcl-2 members and caspase-3 were assessed. |
2(0,0,0,2) | Details |
| 18949061 | Hendrickson AW, Meng XW, Kaufmann SH: Anticancer therapy: boosting the bang of Bim. J Clin Invest. 2008 Nov;118(11):3582-4. Epub 2008 Oct 23. In this issue of the JCI, Cragg et al. report that inhibition upregulates the proapoptotic Bcl-2 family member Bim but induces little regression of human melanoma xenografts in mice unless the Bcl-2 antagonist ABT-737 is added (see the related article beginning on page 3651). |
2(0,0,0,2) | Details |
| 19641525 | Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD, Grigg AP, Seymour JF, Szer J, Huang DC, Roberts AW: The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia. 2009 Nov;23(11):2034-41. Epub 2009 Jul 30. As chronic lymphocytic leukemia (CLL) is characterized by overexpression of pro-survival BCL2, compounds that mimic its physiological antagonists, the BH3-only proteins, may have a role in treatment of this disease. |
2(0,0,0,2) | Details |
| 19684859 | Keuling AM, Felton KE, Parker AA, Akbari M, Andrew SE, Tron VA: RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One. 2009 Aug 17;4(8):e6651. Recent evidence suggests that anti-apoptotic proteins of the Bcl-2 family are overexpressed in melanoma and may contribute to melanoma's striking resistance to apoptosis. |
2(0,0,0,2) | Details |
| 18599488 | Song JH, Kandasamy K, Kraft AS: ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008 Sep 5;283(36):25003-13. Epub 2008 Jul 3. Because Bcl-2 family members inhibit the ability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis, we investigated whether ABT-737, a small molecule Bcl-2 inhibitor, enhances TRAIL killing. |
2(0,0,0,2) | Details |
| 19008458 | Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, Cohen GM: Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009 Apr 30;113(18):4403-13. Epub 2008 Nov 13. ABT-737 and its orally active analog, ABT-263, are rationally designed inhibitors of BCL2 and BCL-X (L). |
2(0,0,0,2) | Details |